What We Do
Disruptive biopharmaceutical platform technology to treat cancer. Very safe and will supplant chemotherapy. Will also combine with current standard of care in PD-1 inhibitors. We are extending life by 3-4X than the current available treatments. TARGET AUDIENCE: Physicians, patients, Investors, insurance payers - general guidance for logo - please add some detail on the logo. tumor cells, blood vessel, immune response, unleashing the power of the immune system and cells
Our Ideas & Additional Information
Vas (vascular) Gene (key regulator of immune response in tumor environment).